MyClad is a global Phase III study evaluating the efficacy and safety of cladribine capsules for the treatment of generalized Myasthenia Gravis (gMG)
TABRECTA is the brand of Novartis. Natco believes it is the first company to have filed a substantially-complete ANDA
First-in-human Phase-1 study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SUVN-I6107 in healthy subjects
First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations
Also received tentative approval for 137 mg
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
PfizerForAll works within the existing healthcare system and through a growing network of partners to simplify access via established channels and to close gaps in care
The initiation of a second Phase 3 clinical trial for bomedemstat demonstrates company’s commitment to advancing research in myeloproliferative neoplasms (MPNs)
Nor UDCA is likely to be a first-in-class treatment option for NAFLD in India
Approval based on MIRACLE Phase III trial demonstrating a significant and clinically meaningful reduction in asthma exacerbations and improvement in asthma symptom control
Subscribe To Our Newsletter & Stay Updated
